| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Shana A Hall, Ryan P Bell, Syam Gadde, Sheri L Towe, Muhammad Tauseef Nadeem, Peter S McCann, Allen W Song, Christina S Mead. Strengthened and posterior-shifted structural rich-club organization in people who use cocaine. Drug and alcohol dependence. vol 235. 2022-04-12. PMID:35413558. |
people with cocaine use disorder (cud) often have abnormal cognitive function and brain structure. |
2022-04-12 |
2023-08-13 |
Not clear |
| Francina Fonseca, Joan Ignasi Mestre-Pinto, Rocío Rodríguez-Minguela, Esther Papaseit, Clara Pérez-Mañá, Klaus Langohr, Margherita Barbuti, Magí Farré, Marta Torren. BDNF and Cortisol in the Diagnosis of Cocaine-Induced Depression. Frontiers in psychiatry. vol 13. 2022-04-04. PMID:35370811. |
major depressive disorder (mdd) and cocaine use disorder (cud) are related with disability and high mortality rates. |
2022-04-04 |
2023-08-13 |
Not clear |
| Francina Fonseca, Joan Ignasi Mestre-Pinto, Rocío Rodríguez-Minguela, Esther Papaseit, Clara Pérez-Mañá, Klaus Langohr, Margherita Barbuti, Magí Farré, Marta Torren. BDNF and Cortisol in the Diagnosis of Cocaine-Induced Depression. Frontiers in psychiatry. vol 13. 2022-04-04. PMID:35370811. |
the aim of this study is to investigate differences in brain derived neurotrophic factor (bdnf) and cortisol plasmatic levels in patients diagnosed with cud-primary-mdd and cud-induced-mdd and also to compare them to a sample of mdd patients (without cocaine use), a sample of cud (without mdd), and a group of healthy controls (hc) after a stress challenge. |
2022-04-04 |
2023-08-13 |
Not clear |
| Andrea Cippitelli, Madeline Martinez, Gilles Zribi, Gerta Cami-Kobeci, Stephen M Husbands, Lawrence Tol. PPL-138 (BU10038): A bifunctional NOP/mu partial agonist that reduces cocaine self-administration in rats. Neuropharmacology. 2022-04-04. PMID:35378170. |
the search for new and effective treatments for cocaine use disorder (cud) is a priority. |
2022-04-04 |
2023-08-13 |
rat |
| Elie Rizkallah, Violaine Mongeau-Pérusse, Léonardo Lamanuzzi, Sol'Abraham Castenada-Ouellet, Emmanuel Stip, Louis-Christophe Juteau, Suzanne Brissette, Julie Bruneau, Simon Dubreucq, Didier Jutras-Aswa. Cannabidiol effects on cognition in individuals with cocaine use disorder: Exploratory results from a randomized controlled trial. Pharmacology, biochemistry, and behavior. 2022-04-03. PMID:35367279. |
cocaine use disorder (cud) is associated with various cognitive deficits that impede patients' functionality, prognosis and therapeutic outcomes. |
2022-04-03 |
2023-08-13 |
Not clear |
| Diego Angeles-Valdez, Jalil Rasgado-Toledo, Victor Issa-Garcia, Thania Balducci, Viviana Villicaña, Alely Valencia, Jorge Julio Gonzalez-Olvera, Ernesto Reyes-Zamorano, Eduardo A Garza-Villarrea. The Mexican magnetic resonance imaging dataset of patients with cocaine use disorder: SUDMEX CONN. Scientific data. vol 9. issue 1. 2022-04-01. PMID:35361781. |
cocaine use disorder (cud) is a substance use disorder (sud) characterized by compulsion to seek, use and abuse of cocaine, with severe health and economic consequences for the patients, their families and society. |
2022-04-01 |
2023-08-13 |
Not clear |
| Changliang Zhu, Hailiang Li, Xuerui Kong, Yezhong Wang, Tao Sun, Feng Wan. Possible Mechanisms Underlying the Effects of Glucagon-Like Peptide-1 Receptor Agonist on Cocaine Use Disorder. Frontiers in pharmacology. vol 13. 2022-03-18. PMID:35300299. |
cocaine use disorder (cud) is a major public health challenge with a high relapse rate and lack of effective pharmacotherapies; therefore, there is a substantial need to identify novel medications to treat this epidemic. |
2022-03-18 |
2023-08-13 |
Not clear |
| Naresh Damuka, Thomas J Martin, Avinash H Bansode, Ivan Krizan, Conner W Martin, Mack Miller, Christopher T Whitlow, Michael A Nader, Kiran Kumar Solingapuram Sa. Initial Evaluations of the Microtubule-Based PET Radiotracer, [ Frontiers in medicine. vol 9. 2022-03-17. PMID:35295607. |
at present, we have no reliable, non-invasive methods to image mts for cocaine use disorder (cud). |
2022-03-17 |
2023-08-13 |
Not clear |
| Grant M Jones, Matthew K Noc. Exploring protective associations between the use of classic psychedelics and cocaine use disorder: a population-based survey study. Scientific reports. vol 12. issue 1. 2022-02-17. PMID:35173246. |
cocaine use disorder (cud) is a significant public health problem associated with elevated morbidity and mortality within the united states. |
2022-02-17 |
2023-08-13 |
human |
| Violaine Mongeau-Pérusse, Elie Rizkallah, Florence Morissette, Suzanne Brissette, Julie Bruneau, Simon Dubreucq, Guillaume Gazil, Annie Trépanier, Didier Jutras-Aswa. Cannabidiol Effect on Anxiety Symptoms and Stress Response in Individuals With Cocaine Use Disorder: Exploratory Results From a Randomized Controlled Trial. Journal of addiction medicine. 2022-02-09. PMID:35135986. |
individuals with a cocaine use disorder (cud) are more likely to present anxiety, which in turn negatively impacts substance use outcomes. |
2022-02-09 |
2023-08-13 |
Not clear |
| Fiene Marie Kuijper, Uma V Mahajan, Seul Ku, Daniel A N Barbosa, Sheila M Alessi, Sherman C Stein, Kyle M Kampman, Brandon S Bentzley, Casey H Halper. Deep Brain Stimulation Compared With Contingency Management for the Treatment of Cocaine Use Disorders: A Threshold and Cost-Effectiveness Analysis. Neuromodulation : journal of the International Neuromodulation Society. vol 25. issue 2. 2022-02-07. PMID:35125144. |
cocaine is the second most frequently used illicit drug worldwide (after cannabis), and cocaine use disorder (cud)-related deaths increased globally by 80% from 1990 to 2013. |
2022-02-07 |
2023-08-13 |
Not clear |
| Giovanni Martinotti, Mauro Pettorruso, Chiara Montemitro, Primavera Alessandra Spagnolo, Cecilia Acuti Martellucci, Francesco Di Carlo, Fabrizio Fanella, Massimo di Giannantoni. Repetitive transcranial magnetic stimulation in treatment-seeking subjects with cocaine use disorder: A randomized, double-blind, sham-controlled trial. Progress in neuro-psychopharmacology & biological psychiatry. 2022-01-25. PMID:35074451. |
cocaine use disorder (cud) is a chronic and relapsing brain disorder with no approved treatments. |
2022-01-25 |
2023-08-13 |
human |
| Andrea Miuli, Giacomo d'Andrea, Mauro Pettorruso, Gianluca Mancusi, Alessio Mosca, Francesco Di Carlo, Giovanni Martinotti, Massimo di Giannantoni. From a cycle to a period: the potential role of BDNF as plasticity and phase-specific biomarker in cocaine use disorder. Current neuropharmacology. 2022-01-17. PMID:35034597. |
cocaine use disorder (cud) is one of the diseases with the greatest social and health impact, due to the high cost of rehabilitation management and the high risk of dangerous behavior and relapse. |
2022-01-17 |
2023-08-13 |
Not clear |
| Kristen P Morie, Elise E DeVito, Marc N Potenza, Patrick D Worhunsk. Longitudinal changes in network engagement during cognitive control in cocaine use disorder. Drug and alcohol dependence. vol 229. issue Pt A. 2021-12-11. PMID:34753083. |
cocaine use disorder (cud) is characterized by poor cognitive control and has limited empirically supported treatment options. |
2021-12-11 |
2023-08-13 |
Not clear |
| Kristen P Morie, Elise E DeVito, Marc N Potenza, Patrick D Worhunsk. Longitudinal changes in network engagement during cognitive control in cocaine use disorder. Drug and alcohol dependence. vol 229. issue Pt A. 2021-12-11. PMID:34753083. |
thus, this study aimed to investigate longitudinal alterations in functional neural networks associated with cognitive control in cocaine use disorder (cud). |
2021-12-11 |
2023-08-13 |
Not clear |
| Robert Suchting, Charles E Green, Constanza de Dios, Jessica Vincent, F Gerard Moeller, Scott D Lane, Joy M Schmit. Citalopram for treatment of cocaine use disorder: A Bayesian drop-the-loser randomized clinical trial. Drug and alcohol dependence. vol 228. 2021-12-10. PMID:34600245. |
medication development research for cocaine use disorder (cud) has been a longstanding goal in addiction research, but has not resulted in an fda-approved treatment. |
2021-12-10 |
2023-08-13 |
Not clear |
| Derek Blevins, Chamindi Seneviratne, Xin-Qun Wang, Bankole A Johnson, Nassima Ait-Daou. A randomized, double-blind, placebo-controlled trial of ondansetron for the treatment of cocaine use disorder with post hoc pharmacogenetic analysis. Drug and alcohol dependence. vol 228. 2021-12-10. PMID:34600264. |
cocaine use disorder (cud) has significant consequences and there remain no fda-approved pharmacotherapies. |
2021-12-10 |
2023-08-13 |
Not clear |
| Marsida Kallupi, Jenni Kononoff, Philippe A Melas, Johanna S Qvist, Giordano de Guglielmo, Eric R Kandel, Olivier Georg. Deep brain stimulation of the nucleus accumbens shell attenuates cocaine withdrawal but increases cocaine self-administration, cocaine-induced locomotor activity, and GluR1/GluA1 in the central nucleus of the amygdala in male cocaine-dependent rats. Brain stimulation. vol 15. issue 1. 2021-12-10. PMID:34742997. |
both preclinical and clinical studies strongly suggest that deep brain stimulation of the nucleus accumbens (nacc) is a viable target for the treatment of cocaine use disorder (cud). |
2021-12-10 |
2023-08-13 |
rat |
| Spencer B Huggett, Jeffrey S Hatfield, Joshua D Walters, John E McGeary, Justine W Welsh, Trudy F C Mackay, Robert R H Anholt, Rohan H C Palme. Ibrutinib as a potential therapeutic for cocaine use disorder. Translational psychiatry. vol 11. issue 1. 2021-12-10. PMID:34880215. |
no current pharmacologic treatments are available for cocaine use disorder (cud) or cocaine toxicity. |
2021-12-10 |
2023-08-13 |
Not clear |
| Jalil Rasgado-Toledo, Apurva Shah, Madhura Ingalhalikar, Eduardo A Garza-Villarrea. Neurite orientation dispersion and density imaging in cocaine use disorder. Progress in neuro-psychopharmacology & biological psychiatry. vol 113. 2021-12-07. PMID:34758367. |
cocaine use disorder (cud) is characterized by a compulsive search for cocaine. |
2021-12-07 |
2023-08-13 |
human |